About Bafna Pharmaceuticals Limited
Data last updated:
Bafna Pharmaceuticals Limited is a public limited company based in Madras 600 001, Tamil Nadu, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 March 1995 and has been in existence for over 31 years.
The company is registered with the Registrar of Companies (ROC), Chennai, under CIN L24294TN1995PLC030698. Its GSTIN is 33AAACB3109Q1ZR (Tamil Nadu). The company holds 6 GST registrations, of which 1 is active. Its shares are listed on BSE: 532989 and NSE: BAFNAPH.
The company has an authorised share capital of ₹40 Cr and a paid-up capital of ₹23.66 Cr. It is led by directors including Shanmugam Hemalatha (Whole-Time Director) and Vinayak Dinesh Dendukuri (Whole-Time Director).
Its last annual general meeting (AGM) was held on 19 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Tamil Nadu, India – 600001.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹150.62 Cr, a growth of 3.3% compared to the previous year. For the same year it recorded a net profit of ₹11.1 Cr (net margin 7.4%) and EBITDA of ₹15.94 Cr (EBITDA margin 10.6%). The net worth stands at ₹96.15 Cr (up 13.4% YoY). Total assets are valued at ₹137.99 Cr (up 19.6% YoY).
The company has about 381 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Bafna Pharma. As per MCA filings, the company has open charges of ₹68.85 Cr and satisfied charges of ₹169.66 Cr on record. Court records list 113 cases involving the company, including 71 filed by the company and 39 filed against it; 18 cases are pending. The company has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bafnapharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered Address299 Thambu Chetty Streetmadras 600 001 Madras 600 001, Tamil Nadu, India – 600001
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Bafna Pharmaceuticals Limited
The main business activity of Bafna Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Bafna Pharmaceuticals Limited FY 2025-26 filings available
Bafna Pharmaceuticals Limited reported revenue of ₹150.62 Cr (up 3.3% YoY) for FY 2025-26.
Financial Highlights
FY 2019-20 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Balance sheet | |||||||
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Net worth | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Cash & bank | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Cash flow | |||||||
| Cash from operations | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Cash from investing | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Cash from financing | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Balance sheet | |||||||
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Net worth | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Cash & bank | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Cash flow | |||||||
| Cash from operations | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Cash from investing | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Cash from financing | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 | 40.32 |
| Revenue growth (YoY) | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - | - |
| Other income | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 | 1.02 |
| Total expenses | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 | 36.53 |
| EBITDA | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 | 3.79 |
| EBITDA margin | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% | +9.4% |
| Depreciation | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 | 1.58 |
| Interest | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 | 0.62 |
| Profit before tax | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 | 2.61 |
| Tax | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Revenue | 42.47 | 43.63 | 47.17 | 64.96 | 85.32 | 97.67 | 185 |
| Revenue growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| Other income | 0.26 | 1.40 | 31.33 | 1.14 | 1.98 | 46.01 | 1.85 |
| Total expenses | 63.80 | 56.70 | 82.29 | 70.78 | 84.81 | 118 | 162 |
| Employee cost | 10.25 | 9.01 | 7.47 | 6.81 | 6.99 | 10.78 | 14.24 |
| EBITDA | (21.33) | (13.07) | (35.12) | (5.82) | 0.51 | (20.51) | 22.83 |
| EBITDA margin | -50.2% | -30.0% | -74.5% | -9.0% | +0.6% | -21.0% | +12.3% |
| Depreciation | 3.27 | 3.48 | 3.97 | 4.22 | 4.86 | 5.99 | 8.99 |
| Interest | 0.10 | 2.13 | 6.94 | 11.47 | 12.96 | 13.46 | 13.21 |
| Profit before tax | (24.44) | (17.28) | (14.70) | (20.37) | (15.33) | 6.05 | 2.48 |
| Tax | 0.00 | 1.07 | 2.19 | (0.90) | (0.18) | (0.15) | 1.05 |
| Net profit | (2.17) | (19.88) | (44.56) | (19.10) | (14.04) | (29.86) | 1.39 |
| Net profit margin | -5.1% | -45.6% | -94.5% | -29.4% | -16.5% | -30.6% | +0.8% |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 2.37 | 23.66 | 23.66 | 18.66 | 18.66 | 18.66 | 18.66 |
| Reserves & surplus | (6.61) | (4.60) | 14.27 | 20.01 | 39.10 | 53.12 | 50.20 |
| Shareholders' funds (net worth) | 51.12 | 19.06 | 37.93 | 42.67 | 57.76 | 71.78 | 68.86 |
| Minority interest | 0.08 | (0.21) | (0.73) | (0.55) | 0.00 | 0.93 | 0.89 |
| Secured loans | 0.00 | 44.10 | 44.37 | 80.14 | 80.48 | 68.65 | 108 |
| Unsecured loans | 3.02 | 2.13 | 2.17 | 2.24 | 0.00 | 0.00 | 0.00 |
| Total debt | 3.02 | 46.23 | 46.54 | 82.38 | 80.48 | 68.65 | 108 |
| Total liabilities | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Assets | |||||||
| Gross block | 74.13 | 72.91 | 79.77 | 79.65 | 79.67 | 77.36 | 90.61 |
| Net block | 35.01 | 37.05 | 44.89 | 48.61 | 52.61 | 54.56 | 69.28 |
| Capital work in progress | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 16.90 | 16.90 | 16.90 | 0.00 |
| Inventories | 11.41 | 9.28 | 10.67 | 16.74 | 16.38 | 16.12 | 27.40 |
| Sundry debtors | 6.03 | 24.83 | 24.28 | 53.78 | 67.96 | 88.69 | 97.51 |
| Cash & bank balances | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Loans & advances | 10.17 | 11.64 | 10.83 | 4.01 | 35.42 | 19.51 | 28.76 |
| Total current assets | 36.09 | 48.46 | 48.73 | 77.19 | 122 | 127 | 156 |
| Total current liabilities | 17.10 | 47.58 | 36.56 | 38.10 | 49.74 | 54.07 | 50.16 |
| Net working capital | 18.99 | 0.88 | 12.17 | 39.09 | 72.73 | 73.02 | 106 |
| Total assets | 54.21 | 65.71 | 96.70 | 137 | 139 | 142 | 179 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 | 21.07 |
| Net cash from operating activities | (34.31) | (1.79) | (7.05) | (0.95) | 0.91 | 10.66 | 1.61 |
| Net cash from investing activities | 32.77 | 15.36 | 37.97 | (5.42) | (0.36) | 60.13 | (6.71) |
| Net cash from financing activities | 7.30 | (13.81) | (30.63) | 6.31 | (0.61) | (70.83) | (13.16) |
| Net change in cash | 5.77 | (0.24) | 0.29 | (0.06) | (0.06) | (0.04) | (18.26) |
| Closing cash | 8.48 | 2.71 | 2.95 | 2.66 | 2.71 | 2.77 | 2.81 |
| Particulars | FY 2019-20 | FY 2018-19 | FY 2017-18 | FY 2016-17 | FY 2015-16 | FY 2014-15 | FY 2013-14 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -2.7% | -7.5% | -27.4% | -23.9% | -12.6% | -47.3% | - |
| EBITDA growth | -63.2% | +62.8% | -503.4% | -1241.2% | +102.5% | -189.8% | - |
| PBT growth | -41.4% | -17.6% | +27.8% | -32.9% | - | +144.0% | -54.9% |
| Net income growth | +89.1% | +55.4% | -133.3% | -36.0% | +53.0% | -2248.2% | - |
| Revenue CAGR (3Y) | -13.2% | -20.0% | -21.5% | -29.5% | -21.4% | - | - |
| EBITDA CAGR (3Y) | +54.2% | - | +19.6% | - | -71.7% | - | - |
| Profitability & leverage | |||||||
| Net income margin | -57.6% | -42.1% | -35.8% | -30.0% | -17.8% | +6.4% | +0.8% |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | -1.7% | -11.8% | +9.0% |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | -23.4% | -42.4% | +2.1% |
| Debt / equity | 0.70 | 1.63 | 1.60 | 1.62 | 1.15 | 1.26 | 1.53 |
| Long-term debt / equity | 0.34 | 0.41 | 0.05 | 0.37 | 0.36 | 0.25 | 0.35 |
| Interest cover | -0.41 | -12.87 | -17.75 | -114.24 | -297.93 | -50.79 | 95.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.58 | 0.57 | 0.59 | 0.82 | 1.10 | 1.17 | 2.10 |
| Inventory turnover | 4.11 | 4.37 | 3.44 | 3.92 | 5.32 | 4.53 | 7.48 |
| Debtors turnover | 2.75 | 1.78 | 1.21 | 1.07 | 1.10 | 1.06 | 1.96 |
| EPS (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.31 | 0.75 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (17.93) | 8.06 | 16.03 | 20.73 | 30.96 | 38.47 | 36.91 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 26.58 | 42.24 | 38.29 | 35.47 | 34.62 | 39.06 | 33.19 | 40.32 |
| Revenue growth (YoY) | -23.2% | +8.1% | +15.4% | -12.0% | +4.0% | - | - | - |
| Other income | 1.91 | 1.76 | 1.22 | 1.18 | 0.60 | 1.03 | 0.19 | 1.02 |
| Total expenses | 25.70 | 38.69 | 35.24 | 31.19 | 29.56 | 37.74 | 30.14 | 36.53 |
| EBITDA | 0.88 | 3.55 | 3.05 | 4.28 | 5.06 | 1.32 | 3.05 | 3.79 |
| EBITDA margin | +3.3% | +8.4% | +8.0% | +12.1% | +14.6% | +3.4% | +9.2% | +9.4% |
| Depreciation | 1.78 | 1.66 | 1.57 | 1.47 | 1.37 | 0.22 | 1.66 | 1.58 |
| Interest | 0.94 | 1.03 | 0.86 | 0.86 | 0.91 | 0.82 | 0.64 | 0.62 |
| Profit before tax | 0.07 | 2.62 | 1.84 | 3.13 | 3.38 | 1.31 | 0.94 | 2.61 |
| Tax | 0.00 | (0.13) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 151 | 146 | 152 | 115 | 85.14 | 71.22 | 42.47 |
| Revenue growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| Other income | 4.76 | 2.74 | 3.52 | 3.27 | 1.70 | 0.75 | 0.26 |
| Total expenses | 135 | 137 | 141 | 99.65 | 75.34 | 60.92 | 64.57 |
| Employee cost | 21.92 | 21.03 | 19.03 | 15.87 | 14.65 | 11.98 | 10.25 |
| EBITDA | 15.94 | 9.03 | 11.11 | 15.70 | 9.80 | 10.30 | (22.10) |
| EBITDA margin | +10.6% | +6.2% | +7.3% | +13.6% | +11.5% | +14.5% | -52.0% |
| Depreciation | 6.07 | 4.89 | 5.00 | 5.33 | 5.49 | 4.48 | 3.27 |
| Interest | 3.66 | 2.73 | 2.29 | 2.04 | 0.79 | 0.74 | 0.10 |
| Profit before tax | 10.97 | 4.15 | 7.34 | 11.60 | 5.22 | 5.83 | (25.21) |
| Tax | (0.13) | 0.00 | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 |
| Net profit | 11.10 | 6.37 | 7.27 | 11.12 | 7.38 | 5.83 | (1.88) |
| Net profit margin | +7.4% | +4.4% | +4.8% | +9.6% | +8.7% | +8.2% | -4.4% |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 23.66 | 2.37 |
| Reserves & surplus | 72.49 | 61.15 | 57.18 | 49.80 | 38.31 | 33.11 | (6.78) |
| Shareholders' funds (net worth) | 96.15 | 84.81 | 80.84 | 73.46 | 61.97 | 56.77 | 50.95 |
| Secured loans | 35.63 | 26.70 | 22.89 | 21.42 | 9.04 | 2.50 | 0.00 |
| Unsecured loans | 1.80 | 1.50 | 1.50 | 1.51 | 2.02 | 12.79 | 3.02 |
| Total debt | 37.43 | 28.20 | 24.39 | 22.93 | 11.06 | 15.29 | 3.02 |
| Total liabilities | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Assets | |||||||
| Gross block | 134 | 106 | 99.49 | 94.66 | 87.94 | 79.57 | 74.09 |
| Net block | 81.79 | 58.78 | 40.21 | 40.23 | 38.85 | 35.97 | 34.97 |
| Capital work in progress | 3.13 | 7.31 | 12.27 | 1.50 | 0.00 | 0.83 | 0.21 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 28.90 | 28.09 | 29.64 | 22.22 | 20.28 | 15.44 | 11.41 |
| Sundry debtors | 43.93 | 40.17 | 45.39 | 41.15 | 14.78 | 9.56 | 6.03 |
| Cash & bank balances | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Loans & advances | 14.80 | 13.04 | 17.34 | 16.13 | 15.65 | 22.86 | 9.95 |
| Total current assets | 89.65 | 84.73 | 93.77 | 87.31 | 50.88 | 49.66 | 35.87 |
| Total current liabilities | 37.53 | 37.68 | 40.44 | 31.99 | 16.27 | 14.31 | 17.10 |
| Net working capital | 52.12 | 47.05 | 53.33 | 55.32 | 34.61 | 35.35 | 18.77 |
| Total assets | 138 | 115 | 107 | 97.60 | 73.87 | 72.16 | 53.96 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 | 2.70 |
| Net cash from operating activities | 15.37 | 22.14 | 9.48 | 4.95 | 9.73 | (13.61) | (34.27) |
| Net cash from investing activities | (22.40) | (21.16) | (15.05) | (7.49) | (6.54) | (5.35) | 32.78 |
| Net cash from financing activities | 5.62 | 1.06 | (0.85) | 10.18 | (4.81) | 12.28 | 7.27 |
| Net change in cash | (1.41) | 2.04 | (6.41) | 7.64 | (1.63) | (6.68) | 5.78 |
| Closing cash | 2.02 | 3.43 | 1.40 | 7.81 | 0.17 | 1.80 | 8.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +3.3% | -4.3% | +32.2% | +35.5% | +19.6% | +67.7% | - |
| EBITDA growth | +76.5% | -18.7% | -29.2% | +60.2% | -4.9% | +146.6% | - |
| PBT growth | +164.3% | -43.5% | -36.7% | +122.2% | -10.5% | +9998.0% | -38.3% |
| Net income growth | +74.3% | -12.4% | -34.6% | +50.7% | +26.6% | +410.1% | - |
| Revenue CAGR (3Y) | +9.3% | +19.7% | +28.9% | +39.5% | +25.0% | +14.7% | -13.2% |
| EBITDA CAGR (3Y) | +0.5% | -2.7% | +2.6% | - | - | - | +61.9% |
| Profitability & leverage | |||||||
| Net income margin | +7.4% | +2.9% | +4.8% | +9.8% | +6.1% | +8.2% | -59.4% |
| Return on capital employed | +8.9% | +5.8% | +6.3% | +9.4% | +5.8% | +6.7% | 0.0% |
| Return on net worth | +8.7% | +5.0% | +5.7% | +8.9% | +5.8% | +6.5% | 0.0% |
| Debt / equity | 0.36 | 0.32 | 0.31 | 0.25 | 0.22 | 0.17 | 0.69 |
| Long-term debt / equity | 0.18 | 0.15 | 0.12 | 0.10 | 0.09 | 0.08 | 0.33 |
| Interest cover | 37.08 | 65.94 | 37.48 | 19.67 | 18.33 | 12.71 | -0.39 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.26 | 1.42 | 1.57 | 1.26 | 1.02 | 0.93 | 0.58 |
| Inventory turnover | 5.29 | 5.05 | 5.88 | 5.43 | 4.77 | 5.31 | 4.11 |
| Debtors turnover | 3.58 | 3.41 | 3.52 | 4.12 | 7.00 | 9.14 | 2.75 |
| EPS (₹) | 4.69 | 1.76 | 3.11 | 4.79 | 2.21 | 2.46 | (106.54) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 40.64 | 35.85 | 34.17 | 31.05 | 26.19 | 24.00 | (18.64) |
Auditor Details of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited is audited by Brahmayaa & CO for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Brahmayaa & CO | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals has 7 current directors and 22 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Palamadai Krishnan Sundaresan | Director | 19 Sep 2025 | 1 Years 0 Months | Current |
| Ravichandran Chitra Also directs: Basilic Fly Studio Limited, Proviniti India Private Limited, Rexa Insurance Broking Services Private Limited and 4 more | Director | 12 Nov 2020 | 5 Years 10 Months | Current |
| Shanmugam Hemalatha | Whole-Time Director | 10 Sep 2020 | 6 Years 0 Months | Current |
| Akila Chintalapati Raju | Director | 10 Sep 2020 | 6 Years 0 Months | Current |
| Navin Kumar | Director | 23 Jun 2025 | 1 Years 3 Months | Current |
| Vinayak Dinesh Dendukuri | Whole-Time Director | 26 Jun 2023 | 3 Years 3 Months | Current |
Shareholding Pattern of Bafna Pharmaceuticals Limited
Shareholding for the quarter ended Sep 2026: promoters hold 75.00%, foreign institutional investors hold 9.30%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 15.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% |
| Public | 25.00% | 25.00% | 25.00% | 25.00% |
Charges & Borrowings of Bafna Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Jun 2025 | Others | ₹11.5 Cr | Open |
| 11 Sep 2024 | Others | ₹6.35 Cr | Open |
| 21 Feb 2024 | Others | ₹12 Cr | Open |
| 30 Nov 2023 | Others | ₹12 Cr | Open |
| 05 Jun 2023 | Others | ₹2 Cr | Open |
Total charge records: 19 View all charges
Deals & Funding of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026.
Deals on record (5 of 65)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2017 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, Krypton Investment Consultancy Private Limited , 2 individuals Seller: 3 individuals |
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, 3 individuals Seller: 4 individuals |
| Sep 2015 | Secondary share transfer | Undisclosed | Buyer: Ipo Shareholders- Bafna Pharmaceuticals Limited, 3 individuals Seller: Nirmal Bang Financial Services Private Limited , Monarch Networth Capital Limited , Bull Investments Madras Private Limited , an individual |
| Sep 2014 | Secondary share transfer | Undisclosed | Buyer: Ifin Securities Finance Limited , Ipo Shareholders- Bafna Pharmaceuticals Limited, Sammaan Finserve Limited , an individual Seller: Indiabulls Housing Finance ltd, Indiabulls Securities Ltd -Client Margin Account, Nirmal Bang Financial Services Private Limited , an individual |
| Sep 2013 | Secondary share transfer | Undisclosed | Buyer: Nirmal Bang Financial Services Private Limited , Indiabulls Securities Ltd -Client Margin Account, 2 individuals Seller: 4 individuals |
Full deal history
All 65 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has 113 court cases on record: 71 filed by Bafna Pharmaceuticals, 39 filed against it, 3 where it is another party. 18 cases are pending and 95 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 71 | 12 | 15 |
| District courts | 42 | 27 | 3 |
Cases on record (5 of 113)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by S S Enterprises Private Limited | Pending |
| Madras High Court | Appeal | Filed by the company against Goldleaf Enterprise Private Limited | Disposed |
| District court, Jodhpur Metro, Rajasthan | Civil suit | Filed against the company by Daga Poly Laminators Private Limited | Disposed |
| District court, Jodhpur Metro, Rajasthan | Civil suit | Filed against the company by Daga Poly Laminators Private Limited | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by Yuno Packaging Private Limited | Disposed |
Full case history
All 113 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Associated Brands with Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals operates one associated brand: Bafna Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provider of formulation services for pharmaceutical industry | bafnapharma.com |
Employees and EPFO Compliance at Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has a workforce of 381 employees as of Mar 31, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals has one previous CIN (Corporate Identification Number): U24294TN1995PLC030698. The current CIN is L24294TN1995PLC030698, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24294TN1995PLC030698 | Current |
| U24294TN1995PLC030698 | Previous |
News related to Bafna Pharmaceuticals Limited
Recent Activity on Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited has 38 board changes on record since 1995: 23 appointments and 15 cessations. The latest: Palamadai Krishnan Sundaresan was appointed as Director on 19 Sep 2025.
72 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Bafna Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Bafna Pharmaceuticals Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Bafna Pharmaceuticals Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals has 6 GST registrations: 1 active and 5 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 33AAACB3109Q1ZR | Tamil Nadu | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Bafna Pharmaceuticals Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals is an active public limited company based in Madras 600 001, Tamil Nadu, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 March 1995 (31+ years old) and is registered under CIN L24294TN1995PLC030698. Listed on BSE: 532989 and NSE: BAFNAPH.
Bafna Pharmaceuticals reported revenue of ₹150.62 Cr for FY 2025-26 (up 3.3% YoY) based on standalone financials.
Bafna Pharmaceuticals has 7 current directors:
- Shanmugam Hemalatha - Whole-Time Director
- Vinayak Dinesh Dendukuri - Whole-Time Director
- Palamadai Krishnan Sundaresan - Director
- Ravichandran Chitra - Director
- Akila Chintalapati Raju - Director
- Navin Kumar - Director
- Upendar Mekala Reddy - Director
The GSTIN of Bafna Pharmaceuticals is 33AAACB3109Q1ZR, registered in Tamil Nadu. The company has 6 GST registrations in all, of which 1 is active and 5 are cancelled or inactive.
The CIN (Corporate Identification Number) of Bafna Pharmaceuticals is L24294TN1995PLC030698. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Bafna Pharmaceuticals is listed on both BSE (code: 532989) and NSE (symbol: BAFNAPH).
Bafna Pharmaceuticals has 113 court cases on record: 71 filed by the company and 39 filed against it. 18 are pending. Most are in the high courts.
Bafna Pharmaceuticals was incorporated on 28 March 1995, making it 31+ years old. It is registered with the Registrar of Companies, Chennai.
Bafna Pharmaceuticals has 65 deals on record (49 market trades, 9 secondary share transfers, 6 funding rounds), with disclosed funding of ₹14.58 Cr; the latest was in August 2026.
Palamadai Krishnan Sundaresan was appointed as Director on 19 Sep 2025. Navin Kumar was appointed as Director on 23 Jun 2025. Krishna Yeachuri ceased to be Director on 31 Mar 2025. Bafna Pharmaceuticals has 38 board changes on record in total.